Who is sponsoring DEFENDOR?

DEFENDOR is sponsored by Biocad.

What condition does DEFENDOR study?

DEFENDOR studies Patients With Solid Tumours Who Receive Myelosupressive Therapy.

What drugs are being tested in DEFENDOR?

Interventions: Empegfilgrastim.

Last reviewed 2021-03-23 · How we verify

DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs

NCT04811443 UNKNOWN

This study was designed to evaluate the efficacy and safety of Extimia® (INN - empegfilgrastim) in reducing the frequency, duration of neutropenia, the incidence of febrile neutropenia and infections caused by febrile neutropenia in patients with solid tumours receiving myelosuppressive therapy

Details

Lead sponsor	Biocad
Status	UNKNOWN
Enrolment	500
Start date	Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Jun 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Patients With Solid Tumours Who Receive Myelosupressive Therapy

Interventions

Empegfilgrastim

Countries

Russia